FY2024 Earnings Estimate for Zevra Therapeutics, Inc. Issued By William Blair (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at William Blair reduced their FY2024 EPS estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, March 27th. William Blair analyst T. Lugo now expects that the company will post earnings of ($1.50) per share for the year, down from their prior estimate of ($1.08). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.14) per share.

Several other equities analysts have also recently commented on ZVRA. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Zevra Therapeutics in a research note on Tuesday, March 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, January 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average price target of $20.00.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $5.80 on Friday. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $7.28. The firm has a fifty day simple moving average of $6.17 and a 200-day simple moving average of $5.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 6.31 and a current ratio of 6.31.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. VisionPoint Advisory Group LLC bought a new stake in Zevra Therapeutics in the 3rd quarter valued at $33,000. Public Employees Retirement System of Ohio increased its holdings in Zevra Therapeutics by 52.5% in the 4th quarter. Public Employees Retirement System of Ohio now owns 5,337 shares of the company’s stock valued at $35,000 after buying an additional 1,837 shares during the period. California State Teachers Retirement System bought a new stake in Zevra Therapeutics in the 3rd quarter valued at $36,000. Strs Ohio bought a new stake in Zevra Therapeutics in the 3rd quarter valued at $37,000. Finally, International Assets Investment Management LLC increased its holdings in Zevra Therapeutics by 555.0% in the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after buying an additional 5,550 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.